Rezafungin
CAS 1396640-59-7
WeightAverage: 1226.411
Monoisotopic: 1225.602719729
Chemical FormulaC63H85N8O17
FDA APPROVED 3/22/2023, Rezzayo, To treat candidemia and invasive candidiasis
Drug Trials Snapshot
2-[[(3S,6S,9S,11R,15S,18S,20R,21R,24S,25S,26S)-6-[(1S,2S)-1,2-dihydroxy-2-(4-hydroxyphenyl)ethyl]-11,20,25-trihydroxy-3,15-bis[(1R)-1-hydroxyethyl]-26-methyl-2,5,8,14,17,23-hexaoxo-18-[[4-[4-(4-pentoxyphenyl)phenyl]benzoyl]amino]-1,4,7,13,16,22-hexazatricyclo[22.3.0.09,13]heptacosan-21-yl]oxy]ethyl-trimethylazanium
- Rezafungin ion
- Rezafungin cation
- CD-101
- SP-3025
- G013B5478J
Rezafungin, sold under the brand name Rezzayo (by Melinta Therapeutics), is a medication used for the treatment of invasive candidiasis.[2] It is an echinocandin antifungal[1][4] that acts as a fungal β-glucan synthase inhibitor.[5]
Rezafungin was approved for medical use in the United States in March 2023,[1][6][5] and in the European Union in December 2023.[2][3]
CAS No. : 1631754-41-0
Rezafungin acetate (Synonyms: Biafungin acetate; CD101 acetate; SP-3025 acetate)
Rezafungin acetate (Biafungin acetate) is a next-generation, broad-spectrum, and long-lasting echinocandin. Rezafungin acetate shows potent antifungal activity against Candida spp., Aspergillus spp., and Pneumocystis spp..
SYN
Hughes, D., et al. (2022). Synthesis of echinocandin antifungal agent. (U.S. Patent No. 11,524,980 B2). U.S. Patent and Trademark Office. https://patentimages.storage.googleapis.com/34/d5/c2/1a8cdcfb3fe3db/US11524980.pdf
https://patentscope.wipo.int/search/en/detail.jsf?docId=US327113930&_cid=P11-MAORN7-73998-1
Example 9. Synthesis of Compound 1 from the 3,4-dimethoxyphenylboronate Ester of Anidulafungin—Coupling in the Presence of TFAA
| Patent Number | Pediatric Extension | Approved | Expires (estimated) | |
|---|---|---|---|---|
| US10702573 | No | 2020-07-07 | 2033-03-14 |  |
| US9526835 | No | 2016-12-27 | 2033-03-14 | |
| US8722619 | No | 2014-05-13 | 2032-03-02 | |
| US11197909 | No | 2021-12-14 | 2038-07-14 | |
| US11654196 | No | 2023-05-23 | 2032-03-02 | |
| US11712459 | No | 2023-08-01 | 2037-03-15 | |
| US11819533 | No | 2023-11-21 | 2038-07-11 | |
Medical uses
In the United States, rezafungin is indicated in adults who have limited or no alternative options for the treatment of candidemia and invasive candidiasis.[1]
In the European Union, rezafungin is indicated for the treatment of invasive candidiasis in adults.[2]
Rezafungin, while remaining a hydrophilic compound, exhibits a volume of distribution more than twice that of caspofungin.[7] This pharmacokinetic property has supported its investigation for the treatment of deep-seated Candida infections, including osteomyelitis.[8][9]
Legal status
Rezafungin was approved for medical use in the United States in March 2023,[1][10][11] The FDA granted the application for rezafungin orphan drug, fast track, and priority review designations.[12]
In October 2023, the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Rezzayo, intended for the treatment of invasive candidiasis in adults.[2] The applicant for this medicinal product is Mundipharma GmbH.[2] Rezafungin was approved for medical use in the European Union in December 2023.[3]
Rezafungin is a member of the family of echinocandins that inhibits 1,3-beta-D-glucan synthase. It is developed by Cidara Therapeutics and approved for the treatment of candidaemia and invasive candidiasis in patients aged >= 18 years who have limited or no alternative treatment options. It is an echinocandin, a quaternary ammonium ion, an antibiotic antifungal drug, an azamacrocycle, a homodetic cyclic peptide and an aromatic ether.
Brand names
Rezafungin is the international nonproprietary name.[13]
Rezafungin is sold under the brand name Rezzayo.[2]
References
- ^ Jump up to:a b c d e “Rezzayo- rezafungin injection, powder, lyophilized, for solution”. DailyMed. 8 June 2023. Retrieved 26 December 2023.
- ^ Jump up to:a b c d e f g “Rezzayo EPAR”. European Medicines Agency (EMA). 12 October 2023. Retrieved 27 December 2023. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
- ^ Jump up to:a b c “Rezzayo Product information”. Union Register of medicinal products. 22 December 2023. Retrieved 26 December 2023.
- ^ Zhao Y, Perlin DS (September 2020). “Review of the Novel Echinocandin Antifungal Rezafungin: Animal Studies and Clinical Data”. Journal of Fungi. 6 (4): 192. doi:10.3390/jof6040192. PMC 7712954. PMID 32998224.
- ^ Jump up to:a b Syed YY (June 2023). “Rezafungin: First Approval”. Drugs. 83 (9): 833–840. doi:10.1007/s40265-023-01891-8. PMID 37212966. S2CID 258831091.
- ^ “Rezzayo approved by FDA amid rapid Candida auris spread”. thepharmaletter.com. 23 March 2023.
- ^ Albanell-Fernández M (January 2025). “Echinocandins Pharmacokinetics: A Comprehensive Review of Micafungin, Caspofungin, Anidulafungin, and Rezafungin Population Pharmacokinetic Models and Dose Optimization in Special Populations”. Clinical Pharmacokinetics. 64 (1): 27–52. doi:10.1007/s40262-024-01461-5. PMC 11762474. PMID 39707078.
- ^ Grasselli Kmet N, Luzzati R, Monticelli J, Babich S, Conti J, Bella SD (March 2025). “Salvage therapy of complicated Candida albicans spondylodiscitis with Rezafungin”. European Journal of Clinical Microbiology & Infectious Diseases. doi:10.1007/s10096-025-05117-5. PMID 40163284.
- ^ Viceconte G, Buonomo AR, Esposito N, Cattaneo L, Somma T, Scirocco MM, et al. (April 2024). “Salvage Therapy with Rezafungin for Candida parapsilosis Spondylodiscitis: A Case Report from Expanded Access Program”. Microorganisms. 12 (5): 903. doi:10.3390/microorganisms12050903. PMC 11123963. PMID 38792732.
- ^ “Novel Drug Approvals for 2023”. U.S. Food and Drug Administration (FDA). 22 December 2023. Retrieved 27 December 2023.
- ^ “Drug Approval Package: Rezzayo”. U.S. Food and Drug Administration (FDA). 18 April 2023. Retrieved 27 December 2023.
- ^ New Drug Therapy Approvals 2023 (PDF). U.S. Food and Drug Administration (FDA) (Report). January 2024. Archived from the original on 10 January 2024. Retrieved 9 January 2024.
- ^ World Health Organization (2018). “International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 79”. WHO Drug Information. 32 (1). hdl:10665/330941.
External links
- “Rezafungin Injection”. U.S. Food and Drug Administration. 18 April 2023.
| Clinical data | |
|---|---|
| Trade names | Rezzayo |
| Other names | Biafungin; CD101 |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a623021 |
| License data | US DailyMed: Rezafungin |
| Routes of administration | Intravenous |
| Drug class | Antifungal |
| ATC code | J02AX08 (WHO) |
| Legal status | |
| Legal status | US: ℞-only[1]EU: Rx-only[2][3] |
| Pharmacokinetic data | |
| Excretion | Feces |
| Identifiers | |
| CAS Number | 1396640-59-7 |
| PubChem CID | 78318119 |
| DrugBank | DB16310 |
| UNII | G013B5478J |
| KEGG | D11197 |
| ChEBI | CHEBI:229680 |
| Chemical and physical data | |
| Formula | C63H85N8O17+ |
| Molar mass | 1226.412 g·mol−1 |
- Lamoth F: Novel Therapeutic Approaches to Invasive Candidiasis: Considerations for the Clinician. Infect Drug Resist. 2023 Feb 22;16:1087-1097. doi: 10.2147/IDR.S375625. eCollection 2023. [Article]
- Miesel L, Lin KY, Ong V: Rezafungin treatment in mouse models of invasive candidiasis and aspergillosis: Insights on the PK/PD pharmacometrics of rezafungin efficacy. Pharmacol Res Perspect. 2019 Nov 20;7(6):e00546. doi: 10.1002/prp2.546. eCollection 2019 Dec. [Article]
- Thompson GR 3rd, Soriano A, Cornely OA, Kullberg BJ, Kollef M, Vazquez J, Honore PM, Bassetti M, Pullman J, Chayakulkeeree M, Poromanski I, Dignani C, Das AF, Sandison T, Pappas PG: Rezafungin versus caspofungin for treatment of candidaemia and invasive candidiasis (ReSTORE): a multicentre, double-blind, double-dummy, randomised phase 3 trial. Lancet. 2023 Jan 7;401(10370):49-59. doi: 10.1016/S0140-6736(22)02324-8. Epub 2022 Nov 25. [Article]
- Ong V, Wills S, Watson D, Sandison T, Flanagan S: Metabolism, Excretion, and Mass Balance of [(14)C]-Rezafungin in Animals and Humans. Antimicrob Agents Chemother. 2022 Jan 18;66(1):e0139021. doi: 10.1128/AAC.01390-21. Epub 2021 Oct 18. [Article]
- FDA Approved Drug Products: REZZAYO (rezafungin) injection for intravenous use (March 2023) [Link]
- Globe News Wire: Cidara Therapeutics and Melinta Therapeutics Announce FDA Approval of REZZAYO (rezafungin for injection) for the Treatment of Candidemia and Invasive Candidiasis [Link]
- EMA Summary of Product Characteristics: REZZAYO (rezafungin) solution for infusion [Link]
//////////Rezafungin, Rezzayo, APROVALS 2023, FDA 2023, Rezafungin ion, Rezafungin cation, CD 101, SP 3025, G013B5478J